
BiolInvent (Q3 Update) - Phase II in NSCLC up and Running

Redeye reviews BiolInvent's Q3 report 2025. The company is doubling down on BI-1206 and BI-1808. BI-1808 has two important readouts scheduled in Q4 2025, as does the BI-1206 triple combination (one readout).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BiolInvent (Q3 Update) - Phase II in NSCLC up and Running